Latest Trovagene Inc. Stories
SAN DIEGO, Dec. 4, 2014 /PRNewswire/ -- Trovagene, Inc.
SAN DIEGO, Nov. 26, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D.
Data presented at the EORTC-NCI-AACR International Symposium Demonstrate High Sensitivity and Strong Quantitative Performance with Trovagene's Precision Cancer Monitoring Platform BARCELONA,
Stifel 2014 Healthcare Conference and Cannacord Genuity Medical Technologies and Diagnostics Forum SAN DIEGO, Nov. 12, 2014 /PRNewswire/ -- Trovagene, Inc.
SAN DIEGO, Nov. 6, 2014 /PRNewswire/ -- Trovagene, Inc.
SAN DIEGO, Oct. 29, 2014 /PRNewswire/ -- Trovagene, Inc.
Prospective blinded study demonstrates ability to accurately determine mutational status and monitor response to BRAF inhibitor therapy from urinary cell-free DNA SAN DIEGO, Oct.
BIO Investor Forum to be held October 7-8 in San Francisco, California SAN DIEGO, Oct. 6, 2014 /PRNewswire/ -- Trovagene, Inc.
BRAF V600E assay improves determination of mutational status and allows monitoring of treatment response SAN DIEGO, Oct.
Additional Study Focuses on the Detection and Quantitative Monitoring of EGFR Mutations in Lung Cancer Patients SAN DIEGO, Sept.
- A trick or prank.